Hightide Therapeutics' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial

Reuters

Dec 02, 2025

Hightide <a href="https://laohu8.com/S/LENZ">Therapeutics</a>' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial

HighTide Therapeutics Inc. has announced positive topline results from its Phase III HARMONY trial evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM). The study demonstrated that HTD1801 achieved the primary endpoint, showing greater HbA1c reduction and superior improvements in key cardiometabolic markers compared to dapagliflozin. These results, which have been announced by the company, reinforce the potential of HTD1801 to address metabolic drivers of T2DM progression while delivering cardiometabolic benefits. The company noted that HTD1801 has previously received two Fast Track designations and one Orphan Drug designation from the US FDA. It is not specified if the full results have been or will be presented at a scientific meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251202-11938100), on December 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2588701661"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588701661\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588701661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588701661","market":"nz","top_or_hot":-1,"title":"Hightide Therapeutics' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hightide <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HighTide Therapeutics Inc. has announced positive topline results from its Phase III HARMONY trial evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM). The study demonstrated that HTD1801 achieved the primary endpoint, showing greater HbA1c reduction and superior improvements in key cardiometabolic markers compared to dapagliflozin. These results, which have been announced by the company, reinforce the potential of HTD1801 to address metabolic drivers of T2DM progression while delivering cardiometabolic benefits. The company noted that HTD1801 has previously received two <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations and one Orphan Drug designation from the US FDA. It is not specified if the full results have been or will be presented at a scientific meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251202-11938100), on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hightide Therapeutics' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHightide Therapeutics' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-02 08:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hightide <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HighTide Therapeutics Inc. has announced positive topline results from its Phase III HARMONY trial evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM). The study demonstrated that HTD1801 achieved the primary endpoint, showing greater HbA1c reduction and superior improvements in key cardiometabolic markers compared to dapagliflozin. These results, which have been announced by the company, reinforce the potential of HTD1801 to address metabolic drivers of T2DM progression while delivering cardiometabolic benefits. The company noted that HTD1801 has previously received two <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations and one Orphan Drug designation from the US FDA. It is not specified if the full results have been or will be presented at a scientific meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251202-11938100), on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDLMGZy0:1","article_id":"2588701661","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588701661","pubTimestamp":1764633646,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HighTide Therapeutics Inc. has announced positive topline results from its Phase III HARMONY trial evaluating HTD1801 in patients with type 2 diabetes mellitus . The study demonstrated that HTD1801 achieved the primary endpoint, showing greater HbA1c reduction and superior improvements in key cardiometabolic markers compared to dapagliflozin. These results, which have been announced by the company, reinforce the potential of HTD1801 to address metabolic drivers of T2DM progression while delivering cardiometabolic benefits. The company noted that HTD1801 has previously received two Fast Track designations and one Orphan Drug designation from the US FDA. It is not specified if the full results have been or will be presented at a scientific meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02511":"君圣泰医药-B"},"translate_title":"Hightide Therapeutics的HTD1801在III期糖尿病试验中优于达格列净","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02511":0.9},"content_text":"Hightide Therapeutics' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial\n    \n\n        HighTide Therapeutics Inc. has announced positive topline results from its Phase III HARMONY trial evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM). The study demonstrated that HTD1801 achieved the primary endpoint, showing greater HbA1c reduction and superior improvements in key cardiometabolic markers compared to dapagliflozin. These results, which have been announced by the company, reinforce the potential of HTD1801 to address metabolic drivers of T2DM progression while delivering cardiometabolic benefits. The company noted that HTD1801 has previously received two Fast Track designations and one Orphan Drug designation from the US FDA. It is not specified if the full results have been or will be presented at a scientific meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251202-11938100), on December 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}